These novel medications , Semaglutide , represent a significant advancement in addressing type 2 diabetes and potentially related ailments . They all are classified as GLP-1 pathway stimulators, https://sashaasmc695180.get-blogging.com/41795459/semaglutide-a-comprehensive-examination-into-incretin-compounds